PDB46 The Utilisation and Switching Rates of Neutral Protamine Hagedorn (NPH) Insulin and Long-acting Insulin Analogs in Patients with Type 2 Diabetes in the United Kingdom

Value in Health ◽

10.1016/j.jval.2020.08.643 ◽

2020 ◽

Vol 23 ◽

pp. S513

Author(s):

V.C. Brunetti ◽

O.H.Y. Yu ◽

R.W. Platt ◽

K.B. Filion

Keyword(s):

Type 2 Diabetes ◽

United Kingdom ◽

Insulin Analogs ◽

Nph Insulin ◽

The United Kingdom ◽

Acting Insulin ◽

Neutral Protamine Hagedorn ◽

Long Acting

Download Full-text

PDB17 THE HEALTH CARE COSTS OF LONG-ACTING INSULIN ANALOGS COMPARED WITH NPH INSULIN IN PATIENTS WITH TYPE 2 DIABETES USING A BASAL REGIMEN: A DANISH PERSPECTIVE

Value in Health ◽

10.1016/s1098-3015(10)72264-6 ◽

2010 ◽

Vol 13 (3) ◽

pp. A57

Author(s):

J Gundgaard ◽

T Christensen ◽

TL Thomsen

Keyword(s):

Type 2 Diabetes ◽

Health Care ◽

Health Care Costs ◽

Insulin Analogs ◽

Nph Insulin ◽

Acting Insulin ◽

Long Acting ◽

Care Costs

Download Full-text

A cost comparison of long-acting insulin analogs vs NPH insulin-based treatment in patients with type 2 diabetes using routinely collected primary care data from the UK

Journal of Medical Economics ◽

10.3111/13696998.2014.991788 ◽

2014 ◽

Vol 18 (4) ◽

pp. 273-282 ◽

Cited By ~ 5

Author(s):

Iskandar Idris ◽

Jason Gordon ◽

Carl Tilling ◽

Jiten Vora

Keyword(s):

Type 2 Diabetes ◽

Primary Care ◽

Cost Comparison ◽

Insulin Analogs ◽

Nph Insulin ◽

Primary Care Data ◽

Acting Insulin ◽

Long Acting ◽

The Uk

Download Full-text

PDB3 COST-EFFECTIVENESS ANALYSIS OF INSULIN DETEMIR COMPARED TO NPH INSULIN IN PATIENTS WITH TYPE-2 DIABETES IN THE UNITED KINGDOM

Value in Health ◽

10.1016/s1098-3015(10)65946-3 ◽

2004 ◽

Vol 7 (6) ◽

pp. 735-736

Author(s):

I Smith ◽

AJ Palmer ◽

S Roze ◽

T Kennedy-Martin

Keyword(s):

Type 2 Diabetes ◽

United Kingdom ◽

Cost Effectiveness ◽

Insulin Detemir ◽

Cost Effectiveness Analysis ◽

Nph Insulin ◽

The United Kingdom ◽

Effectiveness Analysis

Download Full-text

Long-Acting Insulin Analogs Versus Insulin Pump Therapy for the Treatment of Type 1 and Type 2 Diabetes

Diabetes Care ◽

10.2337/dc08-s235 ◽

2008 ◽

Vol 31 (Supplement 2) ◽

pp. S140-S145 ◽

Cited By ~ 70

Author(s):

J. C. Pickup ◽

E. Renard

Keyword(s):

Type 2 Diabetes ◽

Insulin Pump ◽

Insulin Pump Therapy ◽

Insulin Analogs ◽

Pump Therapy ◽

Acting Insulin ◽

Long Acting

Download Full-text

(Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus

Cochrane Database of Systematic Reviews ◽

10.1002/14651858.cd005613.pub4 ◽

2020 ◽

Author(s):

Thomas Semlitsch ◽

Jennifer Engler ◽

Andrea Siebenhofer ◽

Klaus Jeitler ◽

Andrea Berghold ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Insulin Analogues ◽

Nph Insulin ◽

Acting Insulin ◽

Isophane Insulin ◽

Long Acting

Download Full-text

Comparative efficacy and safety of long-acting insulin analogs in patients with type 2 diabetes failing on oral therapy: Systemic review and meta-analyses

Journal of Diabetes Investigation ◽

10.1111/j.2040-1124.2011.00187.x ◽

2011 ◽

Vol 3 (3) ◽

pp. 283-293 ◽

Cited By ~ 4

Author(s):

Yan Bi ◽

Xiubin Li ◽

Daizhi Yang ◽

Yuantao Hao ◽

Hua Liang ◽

...

Keyword(s):

Type 2 Diabetes ◽

Oral Therapy ◽

Systemic Review ◽

Efficacy And Safety ◽

Insulin Analogs ◽

Comparative Efficacy ◽

Acting Insulin ◽

Long Acting ◽

Meta Analyses

Download Full-text

Long-Acting Insulin Analogs: A Review of “Real-World” Effectiveness in Patients with Type 2 Diabetes

Current Diabetes Reviews ◽

10.2174/157339911794273892 ◽

2011 ◽

Vol 7 (1) ◽

pp. 61-74 ◽

Cited By ~ 14

Author(s):

Richard F. Pollock ◽

Katrina M. Erny-Albrecht ◽

Anupama Kalsekar ◽

David Bruhn ◽

William J. Valentine

Keyword(s):

Type 2 Diabetes ◽

Real World ◽

Insulin Analogs ◽

Acting Insulin ◽

Long Acting

Download Full-text

Cardiovascular safety of long-acting insulin analogs in type 2 diabetes patients: Is there a better basal insulin?

Journal of Diabetes Investigation ◽

10.1111/jdi.12776 ◽

2017 ◽

Vol 9 (4) ◽

pp. 728-730 ◽

Cited By ~ 3

Author(s):

Chia-Hsuin Chang ◽

Lee-Ming Chuang

Keyword(s):

Type 2 Diabetes ◽

Basal Insulin ◽

Cardiovascular Safety ◽

Insulin Analogs ◽

Acting Insulin ◽

Long Acting ◽

Diabetes Patients

Download Full-text

PDB27 INSULIN GLARGINE AND NPH INSULIN-BASED REGIMENS REVEAL COMPARABLE TOTAL DIRECT TREATMENT COSTS IN TYPE 2 DIABETES PATIENTS.THE LONG-ACTING INSULIN GLARGINE VS. NPH INSULIN COST EVALUATION STUDY IN GERMANY (LIVE-DE)

Value in Health ◽

10.1016/s1098-3015(10)66675-2 ◽

2008 ◽

Vol 11 (6) ◽

pp. A504

Author(s):

T Scholten ◽

R Holle ◽

W Landgraf ◽

A Spiesecke ◽

H Hauner

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Evaluation Study ◽

Treatment Costs ◽

Cost Evaluation ◽

Nph Insulin ◽

Direct Treatment ◽

Acting Insulin ◽

Long Acting

Download Full-text

Direct healthcare costs of patients with type 2 diabetes using long-acting insulin analogues or NPH insulin in a basal insulin-only regimen

Primary Care Diabetes ◽

10.1016/j.pcd.2010.04.004 ◽

2010 ◽

Vol 4 (3) ◽

pp. 165-172 ◽

Cited By ~ 1

Author(s):

Jens Gundgaard ◽

Torsten E. Christensen ◽

Trine Lyager Thomsen

Keyword(s):

Type 2 Diabetes ◽

Basal Insulin ◽

Healthcare Costs ◽

Insulin Analogues ◽

Nph Insulin ◽

Acting Insulin ◽

Direct Healthcare Costs ◽

Long Acting

Download Full-text